Is ALMR a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Alamar Biosciences (ALMR) rests on Consumable pull-through per instrument: Alamar reported average annual pull-through above $400,000 per instrument for 2025, and consumables grew 147% in the second quarter of 2026 against 35% instrument growth. The bear case rests on almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. Analysts covering it publish targets from $34.00 to $45.00 against a $30.55 share price on November 16, 2026, so even the professionals disagree by 30% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
ALMR key stats
At $30.55 on November 16, 2026, Alamar Biosciences (ALMR) has a market cap of $2.1B.
- Market cap
- $2.1B
- Price to book
- 7.0
Market cap, P/E and yield are measured at the $30.55 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Alamar Biosciences (ALMR)?
The last two weeks for Alamar Biosciences, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ALMR closed at $30.55 on November 16, 2026, down 4.1% over the past five trading days (from $31.84).
- On November 4, 2026, Alamar Biosciences filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 3, 2026, Alamar Biosciences filed an 8-K with the SEC reporting quarterly results and a change in its directors or officers (Item 2.02, Item 5.02). Read the 8-K on sec.gov
- On November 4, 2026, TD Cowen raised its target to $36.00 from $34.00 (Buy).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Alamar Biosciences builds tools for measuring proteins in blood and other biofluids at concentrations conventional immunoassays struggle to see. Its core technology, NULISA, pairs antibody capture with a sequencing readout to push sensitivity far below standard ELISA methods, and the ARGO HT system, launched commercially in January 2024, automates the workflow so a lab can run hundreds of samples across a multiplexed panel. The panels are where the recurring money is: NULISAseq Neuro 220 for neurodegeneration work, Inflammation 250, and the newer Immune 340 for translational immunology, plus an eMTBR-tau blood bioassay added to the neuro panel in 2026. Customers are academic labs, biotechs and pharma research groups, more than 300 of them across 25 countries, and the company was founded in 2018 by Yuling Luo, who previously built Advanced Cell Diagnostics. The model is instruments first, consumables after, and the second quarter of 2026 showed that mix working. Revenue reached $29.4 million, up 82% year over year, but the split matters more than the total: instrument sales grew 35% to $7.8 million while consumables grew 147% to $15.5 million, which is what a maturing installed base is supposed to look like. Gross margin widened to 60% from 53%. The company is still spending ahead of that, with $31.2 million of operating expenses producing a $13.2 million quarterly net loss, funded by roughly $250 million of cash and short-term investments left over from the April IPO at $17 a share. Management guided full-year 2026 revenue to $116 million to $120 million, about 59% growth at the midpoint, and the stock rose roughly 31% on August 11, 2026 in response to the results and that first public guidance. That rally did not hold. The shares peaked at $39.61 and closed at $25.60 on October 16, 2026, down about 27% over the past month, though still about 16% above where they first traded and well above the $17 offer. At that price the market cap is about $1.8 billion, roughly 18 times trailing revenue of about $100 million, or around 13 times guided 2026 revenue net of cash. In October the company added former Grail CEO Bob Ragusa to its board and expanded its leadership team, and it reports third-quarter results on November 3, 2026, where consensus expects revenue of about $30.2 million and a loss of about $0.19 a share.
The bull case: what would have to be true for $45.00
The most optimistic published target on ALMR is $45.00, +47.3% from the $30.55 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Consumable pull-through per instrument
Alamar reported average annual pull-through above $400,000 per instrument for 2025, and consumables grew 147% in the second quarter of 2026 against 35% instrument growth. That gap is the whole economic argument for the platform: once an ARGO HT is installed, revenue should recur without another capital sale. Watch whether pull-through holds above the $400,000 mark as newer, less established installs dilute the average.
2. Installed base expansion
The cumulative installed base passed 100 instruments by the end of 2025, spread across more than 300 customers in 25 countries, and management has pointed to a similar pace of placements through 2026. Each placement is a small annuity, so the count compounds into the consumable line with a lag of a few quarters. International expansion is part of this, including the first APAC install at a Hong Kong neurodegenerative disease center.
3. Neurodegeneration research demand
Blood-based protein markers for Alzheimer's and related conditions have become one of the busiest areas in translational research, and the Neuro 220 panel plus the eMTBR-tau assay put Alamar directly in front of that spending. Concentration in one field cuts both ways, so the Immune 340 panel launch is the attempt to widen the base into immunology and oncology work. How quickly non-neuro panels contribute is a reasonable proxy for whether this becomes a platform or stays a niche. A September 2026 Lancet Neurology study used Alamar's technology to show divergent biological responses to Alzheimer's treatment, the kind of published clinical-research use that tends to pull in more panel orders.
4. Margin leverage against the loss
Gross margin moved from 53% to 60% in a year as consumables took a larger share of the mix, which is the normal pattern for this kind of business. Operating expenses rose 89% over the same period, to $31.2 million, so the loss has not narrowed yet. Q2 net loss per share of about $0.20 did beat the roughly $0.32 consensus, and analysts expect a loss near $1.10 a share for 2026 narrowing to about $0.45 in 2027 on revenue of roughly $166 million. With about $250 million of cash on hand the runway is comfortable, and the question is whether revenue growth outruns the spending curve before that cushion becomes a topic.
The bear case: what would have to be true for $34.00
The most pessimistic published target is $34.00, +11.3% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Alamar Biosciences is worth if the risks below bite instead of the drivers above.
Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. Competition is well capitalized: Olink sits inside Thermo Fisher, SomaScan inside Standard BioTools, and Quanterix, Bio-Techne and the mass-spectrometry vendors all sell into the same labs, which means sensitivity and cost per sample claims get tested constantly. The panels are sold for research rather than clinical diagnosis, so any move toward diagnostics would bring regulatory work and cost that is not in today's numbers. Valuation still leaves little slack, with the shares near 18 times trailing revenue while the company loses money each quarter, and the 27% fall over the past month shows how hard a small, recently listed stock can reprice without any change in reported numbers. The IPO was in April 2026 and typical lockup arrangements expire around six months after listing, which falls in mid-October 2026 and can put additional shares into a thinly traded float. The November 3 third-quarter report is the next test of the $116 million to $120 million full-year guide.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding ALMR already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on ALMR
5 analysts cover ALMR, with an average target of $37.00 (+21.1% against $30.55) and a split of 4 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the ALMR forecast and price target page.
How is ALMR valued?
Market cap, P/E and dividend yield at today's price are in the ALMR key stats above. The business figures below come from Alamar Biosciences's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$100 million, with Q2 2026 at ~$29.4 million, up ~82% year over year
- 2026 revenue guidance: ~$116 million to $120 million (consensus ~$119 million)
- Gross margin (TTM): ~59% (Q2 2026 ~60%)
- Net loss (TTM): ~$50 million; Q2 2026 EPS ~-$0.20 vs ~-$0.32 expected
- Cash / debt: ~$250 million / ~$51 million at June 30, 2026
As of October 2026: There is no meaningful price to earnings ratio because the company loses money, so the market works off revenue multiples: about 18 times trailing sales, or roughly 13 times the 2026 guide once net cash is taken out, down from above 20 times in August. That is still a premium tools multiple for a platform growing north of 50% with widening gross margin. Five analysts carry a mean target near $35.40, and the November 3 report will show whether third-quarter revenue lands near the roughly $30.2 million consensus.
How do you decide if ALMR is a buy?
Whether ALMR is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ALMR indirectly through an index or sector ETF before adding more.
What would change your mind on ALMR
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Consumable pull-through per instrument stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the ALMR stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ALMR against your real portfolio and see your actual exposure before deciding.
Your questions about Alamar Biosciences
Ask Walnut's AI anything about ALMR and see how it fits what you own.
FAQ
Is ALMR a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Consumable pull-through per instrument, with revenue (ttm) at ~$100 million, with Q2 2026 at ~$29.4 million, up ~82% year over year. The bear case rests on almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. Analysts covering it are spread from $34.00 to $45.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell ALMR?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $34.00, +11.3% from the $30.55 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for ALMR?
+
Consumable pull-through per instrument. Alamar reported average annual pull-through above $400,000 per instrument for 2025, and consumables grew 147% in the second quarter of 2026 against 35% instrument growth. The most optimistic analyst target on ALMR is $45.00, +47.3% from the $30.55 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for ALMR?
+
Almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers. Competition is well capitalized: Olink sits inside Thermo Fisher, SomaScan inside Standard BioTools, and Quanterix, Bio-Techne and the mass-spectrometry vendors all sell into the same labs, which means sensitivity and cost per sample claims get tested constantly. The panels are sold for research rather than clinical diagnosis, so any move toward diagnostics would bring regulatory work and cost that is not in today's numbers. Valuation still leaves little slack, with the shares near 18 times trailing revenue while the company loses money each quarter, and the 27% fall over the past month shows how hard a small, recently listed stock can reprice without any change in reported numbers. The IPO was in April 2026 and typical lockup arrangements expire around six months after listing, which falls in mid-October 2026 and can put additional shares into a thinly traded float. The November 3 third-quarter report is the next test of the $116 million to $120 million full-year guide. The most pessimistic published target is $34.00, +11.3% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Alamar Biosciences do?
+
Proteomics tools maker selling the ARGO HT instrument and NULISAseq assay panels to research labs on a razor-and-blade model.
What would have to change for ALMR to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Consumable pull-through per instrument) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (almost all of Alamar's revenue comes from research budgets, so academic grant funding, biotech financing conditions and pharma R&D cuts flow straight into orders, and instrument purchases are the first thing a squeezed lab defers) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Alamar Biosciences actually do?
+
It sells laboratory instruments and the reagent kits that run on them, aimed at measuring proteins in blood and other biofluids at very low concentrations. The ARGO HT system automates the workflow, and NULISAseq panels such as Neuro 220, Inflammation 250 and Immune 340 are the consumables that generate recurring revenue. Customers are research labs in academia, biotech and pharma, more than 300 of them across 25 countries.
What is NULISA and why does it matter?
+
NULISA is Alamar's assay chemistry, which combines antibody-based protein capture with a sequencing readout instead of the fluorescence or colorimetric detection a conventional immunoassay uses. It is built for sensitivity: it targets proteins that circulate at concentrations standard ELISA methods cannot reliably read, which is what makes blood-based measurement of neurological markers practical. That sensitivity claim is also what competitors attack, so independent benchmarking studies carry weight in this market.
How does a US investor buy ALMR?
+
ALMR trades on the Nasdaq Global Select Market, so any US broker can buy it in dollars during normal market hours, including fractionally at brokers that support fractional orders. It listed on April 17, 2026 after pricing its IPO at $17 a share. Because it is a recent, small-cap listing with a limited float, spreads and daily swings tend to be wider than in a large-cap stock.
Walnut is informational, not investment advice, and gives no verdict on ALMR. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.